Manila Times Business
U.S. District Court Issues Decision Regarding CINVANTI® Patents
After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron” or the "Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and S
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Diamond drilling program under way at Leviathan Metals’ Central Project, Kalahari Copper Belt, Botswana
2h ago
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
2h ago
Paychex Small Business Jobs Index Improves for a Third Consecutive Month
2h ago
Safe Pro Awarded U.S. Army Order For AI-Powered Threat Analysis Kit Together with Red Cat Black Widow Drones
2h ago